Clinical trial to evaluate the hepatoprotective effect of ZingiVir-H

A pilot randomized controlled clinical trial to evaluate the hepatoprotective effect of ZingiVir-H in patients with elevated liver enzyme panel - nil

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057467

Enrollment

Registered

2023-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K70-K77- Diseases of liver

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of either gender with an age group between 18 - 70 years Subjects having elevated liver enzymes panel due to multiple causes like obesity, hyper triglyceridemia, drug induced liver disease etc. Subjects with fluctuating liver enzyme panel due to unknown reasons. Subjects who are willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: Patients with chronic liver diseases Pregnant and lactating women Suspected malignant conditions

Design outcomes

Primary

Measure	Time frame
To evaluate the hepatoprotective effect of LIV-EVER ZingiVir-H in patients with elevated liver enzyme panel Timepoint: CBC, Routine urine, Total Cholesterol (Lipid profile), RBS (FBS), LFT, Total protein, A/G ratio, USG abdomen & Pelvis (If necessary) will be done on 0th, 45th and 90th day to evaluate the hepatoprotective effect of trial drug in elevated liver enzyme panels	—

Secondary

Measure	Time frame
To evaluate the additional therapeutic benefits of ZingiVir-H in patients with elevated liver enzyme panelTimepoint: Hematinic, anorexia, indigestion & weight loss will be assessed on 0th, 45th & 90th day to evaluate the additional therapeutic benefits	—

Countries

India

Contacts

Public ContactDr Shan Sasidharan

Pankajakasthuri Herbal Research Foundation

drshan@pkhil.com9188325339

Outcome results